Tag: Infection Risk
-
Immune Complications Drive Higher Infection Risk in Advanced Myeloma Therapies
Overview: A New Frontier in Multiple Myeloma Treatment Chimeric Antigen Receptor (CAR T-cell) therapy and bispecific antibody (BsAb) therapy have transformed the management of advanced multiple myeloma (MM). These immunotherapies mobilize the patient’s own immune system to target and destroy malignant plasma cells, offering durable responses for many who have exhausted conventional therapies. Yet, with…
-
Addressing Infection Risks: Immune Complications in CAR T-Cell and Bispecific Antibody Therapies for Advanced Multiple Myeloma
Understanding the Shift in Multiple Myeloma Treatment Advances in multiple myeloma (MM) have ushered in a new era of immunotherapies, notably Chimeric Antigen Receptor (CAR) T-cell therapy and bispecific antibody (BsAb) therapy. These approaches leverage the patient’s own immune system to target myeloma cells, often achieving deep and lasting responses where traditional therapies fall short.…
-
Immune Complications Elevate Infection Risk in MM Therapies
Overview: Why Immune Complications Matter in Advanced Multiple Myeloma Therapies Chimeric Antigen Receptor (CAR-T) cell therapy and bispecific antibodies (BsAbs) have transformed the treatment landscape for multiple myeloma (MM), offering deep and durable responses for patients with relapsed or refractory disease. Yet, these immune-based therapies also bring new challenges. Immune complications, including impaired humoral and…
-
Azelastin Nasal Spray: A New Hope Against COVID-19
Introduction to Azelastin Nasal Spray In the ongoing fight against COVID-19, researchers continuously seek effective preventive measures. A recent study has shown promising results regarding the nasal spray containing Azelastin. This spray, traditionally used for allergies, has been found to significantly lower the risk of COVID-19 infection. The Study Results According to the latest research,…